“Is Heather Bresch here?”
The mock roll call from Rep. Mark Pocan (D-Wis.) was orchestrated largely in jest. In front of him stood six empty shares and an empty table, topped by six nameplates without faces to match. Bresch, the CEO of the generic drug maker Mylan, was not there. Nor were the other five pharmaceutical industry executives who progressive lawmakers had “invited” to testify, and whose names Pocan called out to be met by silence and snickers from a room of left-leaning drug pricing advocates.